Showing results (231-240 of 413) with videos related to
Sort By:
Pageof 42
Deutsches Arzteblatt International|May 9, 2018
Adverse Drug Reactions (ADR) and EmergenciesA Marlen Schurig, Miriam Böhme, Katja S Just, et al.Nature Reviews. Disease Primers|May 19, 2016
Colorectal cancerErnst J Kuipers, William M Grady, David Lieberman, et al.Journal for Immunotherapy of Cancer|January 17, 2025
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokinesAnton Lahusen, Nora Minhöfer, Kim-André Lohse, et al.Gut|August 25, 2010
Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumoursNinel Azoitei, Ganesh Varma Pusapati, Alexander Kleger, et al.BMC Surgery|January 10, 2009
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancerAndre Mihaljevic, Peter Büchler, Jan Harder, et al.Theranostics|April 17, 2023
Single-cell profiling of GP2-enriched pancreatic progenitors to simultaneously create acinar, ductal, and endocrine organoidsSarah Merz, Markus Breunig, Michael Karl Melzer, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 3, 2020
Smartphone Application to Reinforce Education Increases High-Quality Preparation for Colorectal Cancer Screening Colonoscopies in a Randomized TrialBenjamin Walter, Rena Frank, Leopold Ludwig, et al.Cancer Biology & Therapy|July 25, 2012
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapyRemko Prevo, Emmanouil Fokas, Philip M Reaper, et al.Cancers|October 29, 2020
Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa StudyBeate Schultheis, Dirk Strumberg, Jan Kuhlmann, et al.Anti-Cancer Drugs|July 17, 2014
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding studyMareile Joka, Stefan Boeck, Christoph J Zech, et al.Pageof 42